Eli Lilly COVID-19 antibody trial paused due to safety concerns

El Lilly & Co. paused enrollment of participants in a clinical trial of its antibody treatment for COVID-19 due to a potential safety concern, pushing down the company’s shares. An independent data safety monitoring board recommended pausing enrollment in the U.S. government-sponsored trial, a company spokeswoman said in an emailed statement. The...